Flat Out Love, an initiative to connect breast cancer survivors who are opting not to undergo breast reconstruction after ...

Between 2012 and 2022, incidence rates of breast cancer increased by 1% per year in women older than 50 years and by 1.4% in women younger than 50 years.

Specifically, Enhertu (trastuzumab deruxtecan) has been cleared to treat HR-positive, HER2-low metastatic breast cancer – an immunohistochemistry (IHC) score of 1+ or 2+ or negative for in situ ...

AstraZeneca wants to make its oral selective oestrogen receptor degrader (SERD) drug camizestrant a go-to frontline therapy for HR-positive breast cancer, and made its case at ASCO with data from ...

Story continues below this ad In comparison, the benchmark indices, Sensex and Nifty, ended almost flat. The BSE’s Sensex lost 0.1 per cent, or 82.79 points, to end at 81,361.87. The broader Nifty 50 ...